Your current browser version is out of date, in order not to affect your use, it is recommended that you use the latest Google Browser, Firefox browser, 360 browser, after changing the browser use more smoothly! (note! Dual-core browser please switch to speed mode)
19 October 2022
Announcement: New Board Members of the ACSE

  We are excited to expand our board with two new industry experts Dikran Toroser and Mingfang Lu to help us achieve our goal, by bringing their diverse expertise and insight to our mission.

  Dr. Dikran Toroser, Ph.D. CMPP

  Director | The ACSE

  Sr. Director | Publication Management

  Vaccines & Infectious Disease Lead

  Merck & Co. Inc

  About Dikran Toroser:

  Dikran was educated in the UK and has a Ph.D. in Biochemistry from Newcastle upon Tyne (UK). He did his post-doc at the Cambridge lab (UK) on genetics and then moved to the US to work as a biochemist/researcher for the USDA and NCSU.

  He has worked in big pharma since 2004, most recently as a Publications Group Lead. Dikran has an extensive background in publication planning as well as medical writing. He has held leadership roles in many therapeutic areas, including Immunology, hematology, rare diseases, cardiovascular, and neuroscience.

  Dikran is active in publications-related professional organizations (AMWA and ISMPP) and most recently has been involved in compiling guidelines for the publication’s profession (eg, AMWA/EMWA/ISMPP Joint Position Statements and “GPP”). He is one of the founder faculty for the UC San Diego medical writing certificate and a consulting director.

  Prof. Dr. Mingfang Lu

  Regional Director (China) | The ACSE

  Executive President

  KEO_AiScholar

  About Mingfang Lu:

  Mingfang is a Ph.D. from Tsinghua University, China. He is of vast working experience with top research institutions in China and beyond, including MOST, CAST, NSFC, CAS, CPS, Tsinghua University, Peking University, the Weizmann Institute of Science, the Swedish Institute of Space Physics (IRF), the Soltan Institute for Nuclear Studies in Warsaw, Nihon University, RWTH, etc. He has severed as the Editor-in-Chief at IOP Publishing for 16 years. Mingfang led and conducted institutional visits and talks/seminars for authors and researchers at over 100 top Chinese universities and CAS institutes.

  Dr. Mingfang has been working with Enago (Crimson Interactive) from 2018 to May 2021 as General Manager. His sixteen-year service with IOP Publishing as Chief Representative/Editor-in-Chief – China, FInstP, focused on publishing editorial and best practices, marketing, and the growth of the organization. During his career, the published paper content increased 20 times more i.e., from 200 to 5,000 per year, while simultaneously increasing sales in China and gaining partnership publishing with 8 top Chinese journals.